HUTCHMED (NASDAQ:HCM) Shares Gap Down – What’s Next?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM) gapped down before the market opened on Monday . The stock had previously closed at $16.53, but opened at $15.69. HUTCHMED shares last traded at $15.48, with a volume of 25,271 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Stock Performance

The stock’s 50-day moving average is $14.58 and its two-hundred day moving average is $16.63. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new stake in HUTCHMED in the third quarter worth about $35,000. Barclays PLC boosted its stake in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Blue Trust Inc. increased its holdings in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after buying an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC lifted its position in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after buying an additional 1,647 shares in the last quarter. Finally, OLD Mission Capital LLC purchased a new stake in HUTCHMED during the 4th quarter worth approximately $230,000. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.